

2/4/2008

PTO/SB/08a (05-07)

Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10599327
	Filing Date		2007-03-12
	First Named Inventor	Nariyoshi Shinomiya	
	Art Unit	1646	
	Examiner Name		
Attorney Docket Number		VAN67 P328A	

U.S. PATENTS								
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.								
U.S. PATENT APPLICATION PUBLICATIONS								
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.								
FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button								
NON-PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T <sup>5</sup>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.W./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10599327
	Filing Date		2007-03-12
	First Named Inventor	Nariyoshi Shinomiya	
	Art Unit	1646	
	Examiner Name		
	Attorney Docket Number	VAN67 P328A	

1	BIRCHMEIER C, et al. MET, METASTASIS, MOTILITY AND MORE. Nat Rev Mol Cell Biol, No. 4: 915-925 (December 2003).	<input type="checkbox"/>
2	COTELLA N, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. Vol 17: pp. 1162-1164 (June 2003).	<input type="checkbox"/>
3	FIRE A, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (London) Vol 391: pp. 806-811 (February 1998).	<input type="checkbox"/>
4	GHERARDI E, et al. Hepatocyte Growth Factor-Scatter Factor: Mitogen, Motogen, and Met. Cancer Cells (Cold Spring Harbor) Vol 3: pp. 227-232 (June 1991).	<input type="checkbox"/>
5	HERYNK M, et al. Down-Regulation of c-Met Inhibits Growth in the Liver of Human Colorectal Carcinoma Cells. Cancer Research Vol 63: pp. 2990-2996 (June 1, 2003).	<input type="checkbox"/>
6	LIN S, et al. D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections. Curr Cancer Drug Targets Vol 1: pp. 241-247 (2001).	<input type="checkbox"/>
7	MAEMONDO M, et al. Targeting Angiogenesis and HGF Function Using an Adenoviral Vector Expressing the HGF Antagonist NK4 for Cancer Therapy. Molecular Therapy Vol 5 (No. 2): pp. 177-185 (February 2002).	<input type="checkbox"/>
8	PADDISON P, et al. RNA interference: the new somatic cell genetics? Cancer Cell Vol 2: pp. 17-23 (July 2002).	<input type="checkbox"/>
9	RONG S, et al. Tumorigenicity of the met Proto-Oncogene and the Gene for Hepatocyte Growth Factor. Mol Cell Biology Vol 12 (No. 11): pp. 5152-5158 (November 1992).	<input type="checkbox"/>
10	SHINOMIYA N, et al. Suppression of Met Expression: A Possible Cancer Treatment. Clinical Cancer Research Vol 9: pp.5085-5090 (November 1, 2003).	<input type="checkbox"/>
11	SUI G, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci Vol 99 (No. 8): pp. 5515-5520 (April 16, 2002).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10599327
	Filing Date		2007-03-12
	First Named Inventor	Nariyoshi Shinomiya	
	Art Unit	1646	
	Examiner Name		
	Attorney Docket Number	VAN67 P328A	

	12	TUSCHL T, et al. Targeted mRNA degradation by double-stranded RNA in vitro. Genes & Development Vol 13: pp. 3191-3197 (October 1999).	<input type="checkbox"/>
--	----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Louis Wollenberger/	Date Considered	03/20/2009
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.W./